Abbvie spent $1.2 billion to acquire an antidepressant
Abbvie (ABBV.US) announced that it will acquire an experimental depression treatment drug from Gilgamesh Pharmaceuticals for up to $1.2 billion.
According to the agreement, Abbvie will acquire Gilgamesh's leading drug butrisaloxone, which is under development for the treatment of major depressive disorder
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments